Keyphrases
Adoptive Cell Therapy
100%
Myxoma Virus
100%
Brain Tumor
100%
Murine Melanoma
100%
Rapamycin Treatment
100%
Tumor
80%
T Cells
60%
Virus
40%
Adoptive Transfer
40%
Rapamycin
40%
T-cell Mediated
20%
T Cell Response
20%
Virotherapy
20%
Oncolytic
20%
Melanoma
20%
Metastatic Melanoma
20%
CD8+
20%
Adoptive Therapy
20%
Neutralizing Antibodies
20%
IFN Production
20%
Syngeneic
20%
Survival Time
20%
Innate Immune Cells
20%
Tumor-specific T Cells
20%
Intratumoral Injection
20%
Adoptive Immunotherapy
20%
Triple Therapy
20%
Tumor Destruction
20%
Oncolytic Effect
20%
Therapeutic Gene
20%
Transient Infection
20%
Medicine and Dentistry
T Cell
100%
Cell Therapy
100%
Myxoma Virus
100%
Rapamycin
100%
Melanoma
100%
Intracranial Tumor
100%
Neoplasm
83%
Adoptive Transfer
33%
Virus
33%
In Vitro
16%
Infection
16%
Immunocompetent Cell
16%
Virotherapy
16%
Side Effect
16%
Metastatic Melanoma
16%
T-Cell Response
16%
Combination Therapy
16%
Specific Tumor
16%
Neutralizing Antibody
16%
CD8 Antigen
16%
Survival Time
16%
Adoptive Immunotherapy
16%
Intratumoral Drug Administration
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Melanoma
100%
Myxoma Virus
100%
Rapamycin
100%
Intracranial Tumor
100%
Infection
16%
Immunotherapy
16%
Virotherapy
16%
Side Effect
16%
Metastatic Melanoma
16%
Combination Therapy
16%
CD8 Antigen
16%
Neutralizing Antibody
16%
Survival Time
16%
Immunology and Microbiology
Sirolimus
100%
T Cell
100%
Myxoma Virus
100%
Virus
28%
Immunocompetent Cell
14%
Virotherapy
14%
CD8
14%
Syngenic
14%
Neutralizing Antibody
14%
Survival Time
14%
Adoptive Immunotherapy
14%
Peptides
14%